Bamf Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAMF
BAMF has two approved drugs.
Drugs and US Patents for Bamf
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bamf | SODIUM FLUORIDE F-18 | sodium fluoride f-18 | INJECTABLE;INTRAVENOUS | 216126-001 | Dec 6, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bamf | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 216125-001 | Mar 11, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

